|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Cochi, S.L. 1983. Personal communication. Centers for Disease Control, Atlanta, Ga. Egan, W.M., F.-P.Tsui, and G.Zon. 1982. Structural studies of the Haemophilus influenzae capsular polysaccharides. Pp. 185–196 in Haemophilus influenzae, S.H.Sell and P.P.Wright, eds. New York: Elsevier Science. Eskola, J., H.Peltola, P.H.Mäkelä, H.Käyhty, V.Karanko, J.Samuelson, and L.K.Gordon. 1985. Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/ diphtheria toxoid conjugate vaccine. Lancet I:1184–1186. Fothergill, L.D., and J.Wright. 1933. Influenzal meningitis; relation of age incidence to the bactericidal power of blood against the causal organism. J. Immunol. 24:273–284. Gordon, L.K. 1985. Personal communication, Connaught Research Institute, Ontario, Canada. Griffiss, J.M. 1985. Personal communication, School of Medicine, University of California, San Francisco. Hansen, E.J., C.F.Frisch, K.H.Johnston. 1982a. Cell envelope proteins of Haemophilus influenzae type b: Potential vaccination candidates. Pp. 197–206 in Haemophilus influenzae, S.H.Sell and P.F.Wright, eds. New York: Elsevier Science. Hansen, E.J., S.M.Robertson, P.A.Gulig, C.F.Frisch, E.J.Haanes. 1982b. Immunoprotection of rats against Haemophilus influenzae type b disease mediated by monoclonal antibody against a Haemophilus outer-membrane protein. Lancet I (8268):366–368. Hill, J.C. 1983. Summary of a workshop on Haemophilus influenzaetype b vaccines. J. Infect. Dis. 148:167–175. Institute of Medicine. 1985. New Vaccine Development: Establishing Priorities, Volume I. Diseases of Importance in the United States. Washington, D.C.: National Academy Press. King, S.D., A.Ramlal, H.Wynter, K.Moodie, D.Castle, J.S.C.Kuo, L. Barnes, and C.L.Williams. 1981. Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age. Lancet II (8249):705–709. Lepow, M.L., J.S.Samuelson, and L.K.Gordon. 1985. Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. J. Pediatrics 106:185–189. Loeb, M.R., and D.H.Smith. 1980. Outer membrane protein composition in disease isolates of Haemophilus influenzae: Pathogenic and epidemiological implication. Infect. Immun. 30(3):709–717. Mäkelä, P.H., J.Peltola, H.Käyhty, H.Jousimies, O.Pettay, E. Ruoslahti, A.Sivonen, and O.-V.Renkonen. 1977. Polysaccharide vaccine of group A Neisseria meningtitidis and Haemophilus influenzae type b: Field trial in Finland. J.Infect. Dis. 136(Suppl.):S43–50. Myerowitz, R.L., and C.W.Norden. 1977. Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis. Infect. Immun. 16 (1):218–225.
|
|
|||||||||||||||
